(Q45741261)

15 December 2017

title

Treatment of chronic hepatitis B virus infection: who, when, what for and how. (English)

1 reference

15 December 2017

1 reference

1 reference

1

0 references

publication date

1 May 2000

1 reference

Journal of Gastroenterology and Hepatology

15 December 2017

published in

1 reference

15 December 2017

volume

15 Suppl

1 reference

15 December 2017

page(s)

E31-3

1 reference

Review: Present and future directions in the treatment of chronic hepatitis B infection

15 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.2000.02099.X

Current therapeutic trends in therapy for chronic viral hepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.2000.02099.X

Treatment of chronic hepatitis B virus infection: an Asia-Pacific perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.2000.02099.X

A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.2000.02099.X

Efficacy of lamivudine in patients with hepatitis B e antigen-negative/hepatitis B virus DNA-positive (precore mutant) chronic hepatitis B. Lamivudine Precore Mutant Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.2000.02099.X

Acute exacerbation and hepatitis B virus clearance after emergence of YMDD motif mutation during lamivudine therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.2000.02099.X

Drug therapy for chronic hepatitis B: antiviral efficacy and influence of hepatitis B virus polymerase mutations on the outcome of therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.2000.02099.X

Lamivudine therapy of WHV-infected woodchucks.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.2000.02099.X

Natural history of chronic hepatitis B virus infection in Taiwan: studies of hepatitis B virus DNA in serum

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.2000.02099.X

Acute exacerbations of chronic type B hepatitis are accompanied by increased T cell responses to hepatitis B core and e antigens. Implications for hepatitis B e antigen seroconversion

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.2000.02099.X

Incidence, determinants and significance of delayed clearance of serum HBsAg in chronic hepatitis B virus infection: a prospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.2000.02099.X

Role of hepatitis C virus in dual and triple hepatitis virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.2000.02099.X

The development of cirrhosis in patients with chronic type B hepatitis: A prospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.2000.02099.X

Infectious mononucleosis hepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.2000.02099.X

10.1046/J.1440-1746.2000.02099.X

21 January 2018

Identifiers

DOI

1 reference

15 December 2017

1 reference